← Leaderboards
Celeste M Lindley
University Of North Carolina Chapel Hill
$2,353,422
Attributed
$2,353,422
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $71.1K · FY2005–07$100K$75K$50K$25K$0
'05
'06
'07
Funding mix
By agency
NIH$2,353,422 · 8
By mechanism
M01$2,353,422 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Marty W Mayo$7,773,202
- Melanie S Joy$4,717,709
- Jian None Liu$13,658,713
- Robert N Golden$31,944,665
- Scott H Donaldson$8,054,486
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectPharmacokineticsOral AdministrationDrug Screening /EvaluationEnzyme ActivityCytochrome P450TopotecanGlomerular Filtration RateCombination ChemotherapyEtoposideDrug InteractionsLiver MetabolismNeoplasm /Cancer ChemotherapyHuman Therapy EvaluationEnzyme Induction /RepressionClearance RateLactonesDexamethasoneCarboplatinClinical Trial Phase ISmall Cell Lung CancerHomologous TransplantationBusulfan
Grant awards (24)
CYP2B6 GENOTYPE-PHENOTYPE AND THE INFLUENCE OF SEX AND ETHNICITY$55,524
M01 · FY2007 · RR · contact PI
EVALUATING THE EFFECT OF APREPITANT ON CYCLOPHOSPHAMIDE PHARMACOKINETICS$11,442
M01 · FY2007 · RR · contact PI
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA$4,127
M01 · FY2007 · RR · contact PI
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA$1,239
M01 · FY2006 · RR · contact PI
VALIDATING BUPROPION AS AN IN VIVO PROBE FOR HUMAN CYTOCHROME P450 2B6$9,425
M01 · FY2005 · RR
Validating Bupropion as an In Vivo Probe for Human Cytochrome P450 2B6$35,661
M01 · FY2004 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$190,747
M01 · FY2002 · RR
MAXIMUM TOLERATED SYSTEMIC EXPOSURE (MTSE) TO TOPOTECAN$190,747
M01 · FY2002 · RR
MAXIMUM TOLERATED SYSTEMIC EXPOSURE (MTSE) TO TOPOTECAN$294,555
M01 · FY2001 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$294,555
M01 · FY2001 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$190,747
M01 · FY2001 · RR
MAXIMUM TOLERATED SYSTEMIC EXPOSURE (MTSE) TO TOPOTECAN$190,747
M01 · FY2001 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$294,555
M01 · FY2000 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$294,555
M01 · FY2000 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$294,555
M01 · FY2000 · RR
DEXAMETHASONE ON CYTOCHROME P450 3A4 ACTIVITY$241
M01 · FY2000 · RR
TOPOTECAN W/ CARBOPLATIN &ETOPOSIDE IN SMALL CELL LUNG CA$0
M01 · FY2000 · RR
DOSE VALIDATION IN ALLOGENEIC BONE MARROW TRANSPLANTS$0
M01 · FY2000 · RR
DOSE VALIDATION IN ALLOGENEIC BONE MARROW TRANSPLANTS$0
M01 · FY2000 · RR
DOSE VALIDATION IN ALLOGENEIC BONE MARROW TRANSPLANTS$0
M01 · FY2000 · RR
TOPOTECAN W/ CARBOPLATIN &ETOPOSIDE IN SMALL CELL LUNG CA$0
M01 · FY2000 · RR
TOPOTECAN W/ CARBOPLATIN &ETOPOSIDE IN SMALL CELL LUNG CA$0
M01 · FY2000 · RR
DOSE VALIDATION IN ALLOGENEIC BONE MARROW TRANSPLANTS$0
M01 · FY2000 · RR
TOPOTECAN W/ CARBOPLATIN &ETOPOSIDE IN SMALL CELL LUNG CA$0
M01 · FY2000 · RR